Home Bright How to Rebalance Your Portfolio in a Lofty Market

How to Rebalance Your Portfolio in a Lofty Market

Share
how-to-rebalance-your-portfolio-in-a-lofty-market
How to Rebalance Your Portfolio in a Lofty Market
Share

Olivier Le Moal/ShutterstockIf you’ve chosen a target asset allocation—the mix of stocks, bonds, and cash in your portfolio—you’re probably ahead of many investors. But unless you’re investing in a set-and-forget investment option like a target-date fund, your portfolio’s asset mix will shift as the market fluctuates. In a bull market you might get more equity exposure than you planned, or the reverse if the market declines.Rebalancing involves selling assets that have appreciated the most and using the proceeds to shore up assets that have lagged. This brings your portfolio’s asset mix back into balance and enforces the discipline of selling high/buying low. Rebalancing doesn’t necessarily improve your portfolio’s returns, especially if it means selling asset classes that continue to perform well. But it can be an essential way to keep your portfolio’s risk profile from climbing too high. Where and How to RebalanceIf it’s been a while since your last rebalance, your portfolio might be heavy on stocks and light on bonds. A portfolio that started at 60 percent stocks and 40 percent bonds 10 years ago could now hold more than 80 percent stocks.

Share
Related Articles
usda-unveils-new-support-for-ranchers-to-rebuild-cattle-herds
BusinessEconomyUSUS News

USDA Unveils New Support for Ranchers to Rebuild Cattle Herds

The U.S. Department of Agriculture has unveiled a new package of measures...

how-major-us-stock-indexes-fared-aug.-31
BrightBusinessInvestingMarketsPersonal FinanceStocks

How Major US Stock Indexes Fared Aug. 31

Oil prices rose and U.S. stocks fell after American forces struck Iranian...

trump-unveils-new-drug-pricing-deals-with-9-pharmaceutical-companies
BusinessCompaniesExecutive BranchUSUS NewsUS Politics

Trump Unveils New Drug Pricing Deals With 9 Pharmaceutical Companies

President Donald Trump on Aug. 31 announced agreements with nine midsize pharmaceutical...